- Stocks
- Pharma & Healthcare
- Bliss GVS Pharma
Bliss GVS Pharma share price
NSE: BLISSGVSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Bliss GVS Pharma at a glance
Bliss GVS Pharma (NSE: BLISSGVS) closed at ₹638.00 on 22 Oct 2026, up 2.42% on the day. With a market capitalisation of ₹6,766 Cr, it ranks 674th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 53.1× trailing earnings, against a return on equity of 10.8% in FY26. Over the past year the share price has risen 319.4%. Its 52-week range is ₹118.00 (10 Nov 2025) to ₹739.90 (28 Sep 2026); the last close is 13.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹257 Cr (+29.8% year on year) and net profit ₹37 Cr (+122.2%), on a consolidated basis. Promoters held 35.01% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹6,766 CrRank 674 on NSE
- P/E (trailing)
- 53.1×
- Price to book
- 1.91×FY26
- EPS (TTM)
- ₹12.23to Q4 FY26
- ROE
- 10.8%FY26
- ROCE
- 16.2%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 14.5%FY26
- Book value / share
- ₹112.76FY26
- Dividend payout
- 8.2%FY26
- 52-week high
- ₹739.9028 Sep 2026
- 52-week low
- ₹118.0010 Nov 2025
- 1-year return
- +319.4%
- RSI (14-day)
- 45
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.42% | −3.3% | −3.8% | +42.7% | +319.4% |
Bliss GVS Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹184 Cr | ₹218 Cr | ₹210 Cr | ₹198 Cr | ₹207 Cr | ₹244 Cr | ₹218 Cr | ₹257 Cr |
| Revenue YoY | +15.1% | +2.7% | +4.8% | −0.1% | +13.0% | +12.3% | +3.7% | +29.8% |
| Net profit | ₹22 Cr | ₹26 Cr | ₹26 Cr | ₹17 Cr | ₹44 Cr | ₹29 Cr | ₹25 Cr | ₹37 Cr |
| Net profit YoY | +53.9% | −40.3% | −11.2% | — | +100.6% | +11.3% | −4.0% | +122.2% |
| Net margin | 12.0% | 11.8% | 12.3% | 8.4% | 21.4% | 11.7% | 11.4% | 14.4% |
| EPS | ₹1.97 | ₹2.31 | ₹2.27 | ₹1.47 | ₹4.08 | ₹2.58 | ₹2.20 | ₹3.37 |
Bliss GVS Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹577 Cr | ₹747 Cr | ₹752 Cr | ₹770 Cr | ₹810 Cr | — |
| Operating profit | ₹104 Cr | ₹128 Cr | ₹106 Cr | ₹146 Cr | ₹126 Cr | — |
| Net profit | ₹74 Cr | ₹23 Cr | ₹77 Cr | ₹82 Cr | ₹90 Cr | — |
| EPS (₹) | ₹7.00 | ₹1.00 | ₹7.00 | ₹7.00 | ₹8.00 | — |
| Cash from operations | ₹64 Cr | ₹135 Cr | ₹34 Cr | ₹152 Cr | ₹106 Cr | — |
| Total debt | ₹33 Cr | ₹23 Cr | ₹41 Cr | ₹36 Cr | ₹20 Cr | ₹0 Cr |
| Shareholders' equity | ₹808 Cr | ₹819 Cr | ₹884 Cr | ₹967 Cr | ₹1,050 Cr | ₹1,193 Cr |
Bliss GVS Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 35.29% | 35.44% | 35.39% | 35.36% | 35.36% | 35.01% |
| Foreign institutions | 13.18% | 12.65% | 13.27% | 14.54% | 10.45% | 8.07% |
| Domestic institutions | 6.55% | 6.54% | 5.98% | 5.78% | 5.04% | 9.47% |
| Non-institutions | 44.98% | 45.36% | 45.36% | 44.32% | 49.15% | 47.45% |
Bliss GVS Pharma vs peers
The listed Pharma & Healthcare companies nearest to Bliss GVS Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| THYROCAREThyrocare Technologies | ₹470.65 | +3.44% | +11.6% | ₹7,491 Cr | 46.2 | — |
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
| SUPRIYASupriya Lifescience | ₹848.80 | −0.02% | +19.4% | ₹6,831 Cr | 32.7 | — |
| BLISSGVSBliss GVS Pharma | ₹638.00 | +2.42% | +319.4% | ₹6,766 Cr | 53.1 | — |
| SANOFISanofi India | ₹2,845.00 | +0.53% | −40.0% | ₹6,552 Cr | 21.2 | — |
| ENTEROEntero Healthcare Solutions | ₹1,504.20 | −0.19% | +36.0% | ₹6,547 Cr | 57.1 | — |
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
Ask anything about Bliss GVS Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against BLISSGVS's own history. Try: “Why has BLISSGVS moved over the last three months?” · “Backtest a 50-day moving-average crossover on BLISSGVS over five years” · “Compare BLISSGVS with THYROCARE on margins and valuation”
Frequently asked questions about Bliss GVS Pharma
What is the share price of Bliss GVS Pharma today?
Bliss GVS Pharma (NSE: BLISSGVS) last closed at ₹638.00 on 22 Oct 2026. Its 52-week high is ₹739.90 and its 52-week low is ₹118.00.
What is the market cap of Bliss GVS Pharma?
Bliss GVS Pharma's market capitalisation is ₹6,766 Cr (₹6,766 Cr) at the 22 Oct 2026 close, ranking 674th among the NSE companies Pivot tracks.
What is the P/E ratio of Bliss GVS Pharma?
Bliss GVS Pharma trades at a trailing P/E of 53.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.2.
What is the ROE and ROCE of Bliss GVS Pharma?
Return on equity was 10.8% in FY26 and return on capital employed was 16.2% in FY26 (consolidated figures).
Is Bliss GVS Pharma a debt-free company?
Bliss GVS Pharma is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Bliss GVS Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Bliss GVS Pharma reported revenue of ₹257 Cr, +29.8% year on year, and net profit of ₹37 Cr, +122.2% year on year.
How has Bliss GVS Pharma stock performed over the last year?
Bliss GVS Pharma's share price has risen 319.4% over the past year, +42.7% over three months and −3.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Bliss GVS Pharma?
As of 30 Jun 2026: promoters 35.01%, foreign institutions 8.07%, domestic institutions 9.47%, non-institutions 47.45%.
Who are Bliss GVS Pharma's competitors?
The listed Pharma & Healthcare companies closest to Bliss GVS Pharma by market cap are Thyrocare Technologies, Morepen Laboratories, Supriya Lifescience, Sanofi India, Entero Healthcare Solutions and Kovai Medical Center & Hospital.
Is Bliss GVS Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Bliss GVS Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BLISSGVS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text